Scan run #27

Started 13-sep-2026 22:00 · finished 14-sep-2026 00:10 · triggered by cron

Items fetched	Relevant	Stored	New pages
411	132	131	82

New pages this run

The "82" New pages column above counts new wiki pages created across every area (the column name new_mechanisms is a v1 holdover — it covers mechanisms + treatments + subtypes + transplant-timing + symptoms + lifestyle).

Area	Page	Mentions to date
Mechanisms & Pathways	Acquired von Willebrand syndrome in MPN	1
Mechanisms & Pathways	BCL-2/BCL-xL dual inhibition and apoptotic dependence in myeloid neoplasms	1
Mechanisms & Pathways	BET bromodomain epigenetic regulation in MPN	1
Mechanisms & Pathways	Bone marrow mast-cell infiltration and pruritus in MPN	1
Mechanisms & Pathways	CSF1R macrophage/monocyte signaling in MPN	1
Mechanisms & Pathways	Complement C3-driven stromal reprogramming in MPN	1
Mechanisms & Pathways	Cytopenic vs proliferative PMF phenotypes	1
Mechanisms & Pathways	DNMT3A mutations	1
Mechanisms & Pathways	EZH2 mutations	1
Mechanisms & Pathways	Endothelial-to-mesenchymal transition in MPN cardiovascular disease	1
Mechanisms & Pathways	Ferroptosis in MPN and hematological malignancies	1
Mechanisms & Pathways	Glutamate–mGluR5–fumarate metabolic rewiring of MSCs	1
Mechanisms & Pathways	Immune microenvironment dysregulation in MPN	1
Mechanisms & Pathways	MDM2–p53 axis in MPN	1
Mechanisms & Pathways	MF spleen spatial niche compartments (IV/PV/RP)	1
Mechanisms & Pathways	MPN clonal evolution trajectories to transformation	8
Mechanisms & Pathways	Metabolic syndrome as a pathophysiological modifier in polycythemia vera	1
Mechanisms & Pathways	NF-κB signaling in MPN	1
Mechanisms & Pathways	NK cell immune surveillance in MPN	1
Mechanisms & Pathways	Oxidative stress in MPN	1
Mechanisms & Pathways	Oxidative stress, lipid peroxidation, and malondialdehyde (MDA)	1
Mechanisms & Pathways	PIM kinase signaling in MPN	1
Mechanisms & Pathways	TPO/MPL signaling axis	1
Mechanisms & Pathways	Telomerase inhibition in MPN	1
Mechanisms & Pathways	Therapy-associated mutagenesis in MPN	1
Mechanisms & Pathways	Thrombopoietin/MPL signaling in endocardial endothelium	1
Mechanisms & Pathways	UTS (U2AF1/TP53/SRSF2) high-risk mutation signature in SMF	1
Disease Subtypes	Juvenile myelomonocytic leukemia (JMML)	2
Disease Subtypes	MDS/MPN with neutrophilia (aCML)	1
Disease Subtypes	Prefibrotic myelofibrosis (preMF)	6
Disease Subtypes	Secondary myelofibrosis (post-PV/post-ET MF)	35
Symptom Management	Atypical EMH mass-related symptoms (dyspnea, ascites, pain) in MF	2
Symptom Management	Bone pain	2
Symptom Management	Constitutional fever (low-grade / FUO-like)	8
Symptom Management	Splanchnic venous thrombosis	11
Stem Cell Transplant Decisions	Allogeneic HCT in MDS/MPN with neutrophilia	1
Stem Cell Transplant Decisions	Atypical extramedullary hematopoiesis as an early-transplant referral trigger in MF	1
Stem Cell Transplant Decisions	Clofarabine + Melphalan conditioning regimen	1
Stem Cell Transplant Decisions	Fludarabine + Busulfan conditioning regimen	2
Stem Cell Transplant Decisions	MYSEC-mPM / MYSEC-kmPM (molecular/karyotype-augmented MYSEC-PM)	1
Stem Cell Transplant Decisions	Pretransplant splenomegaly debulking in myelofibrosis	1
Stem Cell Transplant Decisions	Reduced-intensity haploidentical HCT in myelofibrosis	3
Stem Cell Transplant Decisions	Tagraxofusp post-transplant maintenance (CD123+ MF/CMML/AML/MDS)	1
Stem Cell Transplant Decisions	Transplant underuse in intermediate-2/high-risk myelofibrosis	10
Treatments	Abemaciclib + Ruxolitinib combination	1
Treatments	Anti-MPL neutralizing antibody	1
Treatments	Axatilimab (CSF1R monoclonal antibody)	1
Treatments	Azacitidine	1
Treatments	Azacitidine (5-AZA)	4
Treatments	Azacitidine + Pacritinib (CMML)	1
Treatments	Azacitidine + Ruxolitinib combination	2
Treatments	BEBT-507	1
Treatments	Clofarabine + Melphalan conditioning regimen	1
Treatments	Decitabine	1
Treatments	Ferroptosis-based treatment strategies	1
Treatments	Flonoltinib maleate	3
Treatments	Gecacitinib	1
Treatments	Imetelstat (telomerase inhibitor)	1
Treatments	Intensive 7+3 induction for secondary/blast-phase AML	1
Treatments	Interferon-α	1
Treatments	Interferon-α (cytoreduction in MPN)	1
Treatments	LP-108 + Azacitidine combination	1
Treatments	Low-dose aspirin	1
Treatments	Low-dose splenic irradiation (pretransplant MF)	1
Treatments	Low-molecular-weight heparin (LMWH)	1
Treatments	Mutant CALR-directed immunotherapy	1
Treatments	Navtemadlin (MDM2 antagonist)	1
Treatments	PXS-5505 (pan-LOX/LOXL inhibitor)	1
Treatments	Palliative hepatosplenic radiotherapy for EMH	1
Treatments	Pharmacological C3 complement inhibition (myelofibrosis)	1
Treatments	Radiotherapy for extramedullary hematopoiesis in MF	1
Treatments	Reduced-intensity haploidentical HCT (myelofibrosis)	1
Treatments	Revumenib (menin inhibitor)	1
Treatments	Selinexor + Azacitidine combination	1
Treatments	Selinexor combination therapy in MDS/MPN overlap syndromes	1
Treatments	Splenectomy for EMH-related complications in MF	1
Treatments	TP-3654 (PIM kinase inhibitor)	1
Treatments	TPO/MPL pathway-targeted therapy	1
Treatments	Tagraxofusp (CD123-directed post-HCT maintenance)	1
Treatments	Trametinib	2
Treatments	Trametinib + Azacitidine (JMML)	1
Treatments	UBP310/UBP296 (mGluR5 inhibitors)	1

Dynamic queries this run

SPEC-V2.4 — the expander proposes new searches for pages that have crossed their mention threshold. They run on subsequent scans alongside the static spec queries.

Metric	Count
New queries proposed	11
Active queries that fired	13
Items pulled in via dynamic queries	78
Queries auto-demoted this run	13

Proposed this run

Page	Source	Query	Rationale	Status
Clonal hematopoiesis	pubmed	`("clonal hematopoiesis"[Title/Abstract] OR "CHIP"[Title/Abstract] OR "clonal haematopoiesis"[Title/Abstract]) AND "JAK2"[Title/Abstract] AND (ropeginterferon[Title/Abstract] OR interferon[Title/Abstract] OR microvascular[Title/Abstract] OR "symptom burden"[Title/Abstract] OR "allele burden"[Title/Abstract] OR Besremi[Title/Abstract])`	Catches JAK2-mutant CHIP/CH papers tied to interferon or microvascular/symptom/allele-burden endpoints that existing TET2/DNMT3A/ASXL1-CHIP and broad ropeginterferon queries miss.	active
Thrombosis risk	pubmed	`("rusfertide"[Title/Abstract] OR "PTG-300"[Title/Abstract] OR "hepcidin mimetic"[Title/Abstract]) AND ("thrombosis"[Title/Abstract] OR "thrombotic"[Title/Abstract] OR "thromboembolic"[Title/Abstract] OR "arterial"[Title/Abstract] OR "venous thromboembolism"[Title/Abstract] OR "hematocrit"[Title/Abstract] OR "cardiovascular event"[Title/Abstract])`	Targets rusfertide/PTG-300 specifically with thrombosis and Hct-control outcome terms, catching confirming or disconfirming evidence beyond the broader hepcidin-axis + MPN query that lacks thrombotic endpoints.	active
Bone marrow fibrosis	pubmed	`("C3"[Title/Abstract] OR "complement C3"[Title/Abstract] OR "C3 inhibitor"[Title/Abstract] OR "complement inhibition"[Title/Abstract] OR pegcetacoplan[Title/Abstract] OR "anti-C3"[Title/Abstract]) AND (myelofibrosis[Title/Abstract] OR "myeloproliferative"[Title/Abstract] OR "bone marrow fibrosis"[Title/Abstract]) AND (splenomegaly[Title/Abstract] OR spleen[Title/Abstract] OR stromal[Title/Abstract] OR "pro-fibrotic"[Title/Abstract] OR fibrosis[Title/Abstract])`	Targets C3/complement inhibition evidence for or against reduced splenomegaly and pro-fibrotic stromal effects in MPN/fibrosis, a niche not covered by existing cytokine, JAK, or generic fibrosis queries.	active
Inflammatory cytokine signaling	pubmed	`("canakinumab"[Title/Abstract] OR anakinra[Title/Abstract]) AND (fatigue[Title/Abstract] OR "IL-1 beta"[Title/Abstract] OR "interleukin-1 beta"[Title/Abstract] OR "IL-1β"[Title/Abstract]) AND (myeloproliferative[Title/Abstract] OR myelofibrosis[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR MPN[Title/Abstract] OR CHIP[Title/Abstract])`	Targets canakinumab/anakinra IL-1β blockade linked to fatigue or IL-1β in MPN/CHIP populations, catching confirming or disconfirming evidence absent from existing IL-6/TNF and drug-specific queries.	active
Exercise and Physical Activity	pubmed	`("exercise"[Title/Abstract] OR "physical activity"[Title/Abstract] OR "exercise training"[Title/Abstract] OR "aerobic exercise"[Title/Abstract] OR "resistance training"[Title/Abstract] OR "exercise program"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR MPN[Title/Abstract])`	Retrieves MPN-specific exercise and physical-activity intervention studies (e.g., fatigue, fitness programs) not covered by existing diet, supplement, thrombosis, or psychosocial lifestyle queries.	active
Bomedemstat	pubmed	`("bomedemstat"[Title/Abstract] OR "IMG-7289"[Title/Abstract] OR "MK-3543"[Title/Abstract]) AND (myeloproliferative[Title/Abstract] OR myelofibrosis[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR MPN[Title/Abstract])`	Captures bomedemstat and its development codes in MPN contexts, which no existing static or dynamic query covers.	active
Fedratinib	pubmed	`"fedratinib"[Title/Abstract] AND (myelofibrosis[Title/Abstract] OR "myeloproliferative"[Title/Abstract] OR "ruxolitinib"[Title/Abstract] OR JAKARTA[Title/Abstract] OR "JAK2"[Title/Abstract])`	No existing query targets fedratinib itself; this pulls MF/MPN and ruxolitinib-failure/JAKARTA literature on this selective JAK2 inhibitor without overlapping ruxolitinib- or pacritinib-only searches.	active
Pacritinib	pubmed	`"pacritinib"[Title/Abstract] AND (myelofibrosis[Title/Abstract] OR "myeloproliferative"[Title/Abstract] OR thrombocytopenia[Title/Abstract] OR IRAK1[Title/Abstract])`	No existing query targets pacritinib itself; this pulls MF/MPN and thrombocytopenia/IRAK1-focused papers on the drug beyond incidental co-mentions in broad JAK-inhibitor comparisons.	active
ACVR1 signaling and hepcidin axis	pubmed	`("ACVR1"[Title/Abstract] OR "ALK2"[Title/Abstract] OR hepcidin[Title/Abstract] OR ferroportin[Title/Abstract] OR momelotinib[Title/Abstract] OR rusfertide[Title/Abstract] OR BMP6[Title/Abstract]) AND (myelofibrosis[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR myeloproliferative[Title/Abstract])`	Pulls ACVR1/ALK2–BMP6–hepcidin–ferroportin axis and ACVR1-inhibitor/hepcidin-targeted agents (momelotinib, rusfertide) in MPN that no existing static or dynamic query covers.	active
Blast-phase MPN and leukemic transformation	pubmed	`("blast phase"[Title/Abstract] OR "blast-phase"[Title/Abstract] OR "MPN-BP"[Title/Abstract] OR "leukemic transformation"[Title/Abstract] OR "leukaemic transformation"[Title/Abstract]) AND (myeloproliferative[Title/Abstract] OR myelofibrosis[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract])`	Targets blast-phase MPN and leukemic transformation specifically—terms absent from existing static and dynamic queries—capturing progression-to-AML mechanisms and mutational context without overlapping broader MPN or cytokine/JAK coverage.	active
Bone marrow fibrosis	pubmed	`("megakaryocyte"[Title/Abstract] OR "megakaryocytes"[Title/Abstract] OR "megakaryopoiesis"[Title/Abstract]) AND ("bone marrow fibrosis"[Title/Abstract] OR "marrow fibrosis"[Title/Abstract] OR "collagen deposition"[Title/Abstract] OR reticulin[Title/Abstract] OR fibrocyte[Title/Abstract]) AND (myelofibrosis[Title/Abstract] OR myeloproliferative[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR "polycythemia vera"[Title/Abstract])`	Catches megakaryocyte- and fibrocyte-driven marrow fibrosis mechanisms that the existing bone-marrow-fibrosis plus TGF-beta/reticulin query does not specifically target.	active

Demoted this run

Page	Source	Query	Reason
ASTX727 (oral cedazuridine + decitabine)	pubmed	`("ASTX727"[Title/Abstract] OR "cedazuridine"[Title/Abstract] OR "oral decitabine"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "MPN"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "CMML"[Title/Abstract] OR "MDS/MPN"[Title/Abstract]) AND ("pharmacokinetics"[Title/Abstract] OR "bioavailability"[Title/Abstract] OR "clinical trial"[Title/Abstract] OR "phase"[Title/Abstract] OR "response"[Title/Abstract])`	0 relevant hits over 9 scans (min 1)
ASTX727 + Venetoclax combination (CMML / MDS-MPN)	pubmed	`"venetoclax"[Title/Abstract] AND ("CMML"[Title/Abstract] OR "chronic myelomonocytic leukemia"[Title/Abstract] OR "MDS/MPN"[Title/Abstract]) AND ("BCL-2"[Title/Abstract] OR "BCL2"[Title/Abstract]) AND ("hypomethylating"[Title/Abstract] OR "azacitidine"[Title/Abstract] OR "decitabine"[Title/Abstract])`	0 relevant hits over 9 scans (min 1)
Inflammatory cytokine signaling	pubmed	`("inflammatory cytokine"[Title/Abstract] OR "cytokine storm"[Title/Abstract] OR "cytokine profile"[Title/Abstract] OR "proinflammatory"[Title/Abstract]) AND ("constitutional symptoms"[Title/Abstract] OR "fatigue"[Title/Abstract] OR "pruritus"[Title/Abstract] OR "clonal advantage"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract])`	0 relevant hits over 9 scans (min 1)
MPL mutations	pubmed	`"MPL"[Title/Abstract] AND ("W515"[Title/Abstract] OR "S505"[Title/Abstract] OR "Y591"[Title/Abstract] OR "R592"[Title/Abstract] OR "exon 10"[Title/Abstract]) AND ("thrombopoietin receptor"[Title/Abstract] OR "JAK2 activation"[Title/Abstract] OR "signaling"[Title/Abstract]) AND ("essential thrombocythemia" OR "myelofibrosis" OR "myeloproliferative")`	0 relevant hits over 9 scans (min 1)
Diet and Nutrition	pubmed	`("Mediterranean diet"[Title/Abstract] OR "anti-inflammatory diet"[Title/Abstract] OR "dietary iron"[Title/Abstract] OR "iron intake"[Title/Abstract] OR "nutrition"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract])`	0 relevant hits over 10 scans (min 1)
Pelabresib (BET bromodomain inhibitor)	pubmed	`"pelabresib"[Title/Abstract] AND ("ruxolitinib"[Title/Abstract] OR "JAK inhibitor"[Title/Abstract] OR "combination therapy"[Title/Abstract] OR "spleen volume"[Title/Abstract] OR "symptom burden"[Title/Abstract]) AND ("myelofibrosis"[Title/Abstract] OR "myeloproliferative"[Title/Abstract])`	0 relevant hits over 10 scans (min 1)
Phlebotomy-only maintenance in PV	pubmed	`"phlebotomy"[Title/Abstract] AND ("polycythemia vera"[Title/Abstract] OR "polycythaemia vera"[Title/Abstract]) AND ("low-risk"[Title/Abstract] OR "maintenance"[Title/Abstract] OR "watchful waiting"[Title/Abstract] OR "aspirin alone"[Title/Abstract] OR "without cytoreduction"[Title/Abstract])`	0 relevant hits over 10 scans (min 1)
INCA033989 (novel investigational agent for MPN)	pubmed	`"INCA033989"[Title/Abstract] OR ("anti-CALR"[Title/Abstract] AND "monoclonal antibody"[Title/Abstract] AND ("myeloproliferative"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR "myelofibrosis"[Title/Abstract]))`	0 relevant hits over 10 scans (min 1)
CALR mutations	pubmed	`("mutant CALR"[Title/Abstract] OR "CALR mutation"[Title/Abstract] OR "calreticulin mutation"[Title/Abstract]) AND ("immunotherapy"[Title/Abstract] OR "antibody"[Title/Abstract] OR "vaccine"[Title/Abstract] OR "targeted therapy"[Title/Abstract] OR "neoantigen"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR "myelofibrosis"[Title/Abstract])`	0 relevant hits over 11 scans (min 1)
JAK-STAT signaling	pubmed	`"JAK2"[Title/Abstract] AND ("STAT3"[Title/Abstract] OR "STAT5"[Title/Abstract]) AND ("signaling pathway"[Title/Abstract] OR "signal transduction"[Title/Abstract] OR "phosphorylation"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract])`	0 relevant hits over 11 scans (min 1)
Mutant-selective JAK2V617F inhibition via JH2 pseudokinase domain	pubmed	`"JH2"[Title/Abstract] AND ("pseudokinase"[Title/Abstract] OR "allosteric"[Title/Abstract]) AND ("JAK2"[Title/Abstract] OR "JAK2V617F"[Title/Abstract] OR "V617F"[Title/Abstract])`	0 relevant hits over 12 scans (min 1)
ASTX727 (oral cedazuridine + decitabine)	pubmed	`("ASTX727"[Title/Abstract] OR "cedazuridine"[Title/Abstract] OR "oral decitabine"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "MPN"[Title/Abstract] OR "MDS/MPN"[Title/Abstract]) AND ("iadademstat"[Title/Abstract] OR "LSD1"[Title/Abstract] OR "decitabine"[Title/Abstract])`	0 relevant hits over 13 scans (min 1)
XPO1 nuclear export	pubmed	`"XPO1"[Title/Abstract] AND ("selinexor"[Title/Abstract] OR "nuclear export"[Title/Abstract] OR "exportin"[Title/Abstract]) AND ("myelofibrosis"[Title/Abstract] OR "myeloproliferative"[Title/Abstract] OR "polycythemia vera"[Title/Abstract])`	0 relevant hits over 13 scans (min 1)